Redeye: Saniona - Early Christmas gift from Mexico

Saniona announced yesterday that the tesofensine phase III trial met its primary and secondary endpoints. We have updated our valuation model accordingly. The news has ripple effects for other Saniona programs which comprise tesofensine.

Read more in the research update by Anders Hedlund: http://bit.ly/2EuQpxg

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/